BCL2L1 and ovarian neoplasm: For instance, patients whose ovarian tumor tissue expresses high BCL-XL levels are less sensitive to taxane treatment, highlighting further the relevance of the addition of BCL-XL inhibitors, such as Navitoclax, to improve taxane-based therapy [44].